Table 2. Univariate and multivariate analysis of leukemia-free survival (LFS) and overall survival (OS).
LFS |
OS |
|||||||
---|---|---|---|---|---|---|---|---|
P-value | Hazard ratio |
95% CI |
P-value | Hazard ratio |
95% CI |
|||
Lower | Upper | Lower | Upper | |||||
Univariate analysis | ||||||||
Male gender | 0.977 | 0.99 | 0.59 | 1.67 | 0.448 | 1.27 | 0.68 | 2.38 |
Age ⩾40 years | 0.807 | 1.07 | 0.63 | 1.80 | 0.013 | 2.31 | 1.20 | 4.48 |
WCC ⩾100 × 109/l | 0.557 | 1.54 | 0.37 | 6.42 | 0.010 | 5.04 | 1.46 | 17.37 |
BM blasts ⩾70% | 0.762 | 0.91 | 0.48 | 1.72 | 0.010 | 2.43 | 1.23 | 4.79 |
>1 induction to CR1 | 0.584 | 0.82 | 0.40 | 1.68 | 0.299 | 1.50 | 0.70 | 3.21 |
HSCT at CR1 | 0.006 | 0.28 | 0.11 | 0.70 | 0.246 | 0.60 | 0.25 | 1.43 |
Mutations in signaling | 0.020 | 3.42 | 1.22 | 9.63 | 0.047 | 4.26 | 1.02 | 17.80 |
Mutations in methylation | 0.030 | 2.26 | 1.08 | 4.72 | 0.940 | 0.96 | 0.37 | 2.50 |
KIT-AL | 0.004 | 2.46 | 1.33 | 4.55 | 0.001 | 3.09 | 1.56 | 6.12 |
TET2 | 0.019 | 2.64 | 1.17 | 5.97 | 0.996 | 1.00 | 0.35 | 2.85 |
RAS | 0.785 | 0.91 | 0.45 | 1.84 | 0.804 | 0.90 | 0.41 | 2.00 |
FLT3 | 0.664 | 0.80 | 0.28 | 2.23 | 0.966 | 0.98 | 0.30 | 3.19 |
RAD21 | 0.284 | 0.57 | 0.20 | 1.60 | 0.406 | 0.61 | 0.18 | 1.98 |
KIT-ALNeg and TET2Neg | 0.001 | 0.35 | 0.19 | 0.65 | 0.015 | 0.43 | 0.22 | 0.85 |
Multivariate analysis | ||||||||
Age ⩾40 years | – | – | – | – | 0.013 | 2.36 | 1.19 | 4.65 |
WCC ⩾100 × 109/l | – | – | – | – | 0.109 | 2.90 | 0.79 | 10.65 |
BM blasts ⩾70% | – | – | – | – | 0.036 | 2.16 | 1.05 | 4.44 |
KIT-AL | 0.001 | 2.84 | 1.50 | 5.36 | – | – | – | – |
TET2 | 0.004 | 3.43 | 1.48 | 7.96 | – | – | – | – |
Abbreviations: AL, activation loop; BM, bone marrow; CI, confidence interval; CR1, first complete remission; HSCT, hematopoietic stem cell transplantation; WCC, white cell count.
KIT-ALNeg and TET2Neg was not entered into multivariate analysis, as it would mutually exclude KIT-AL and TET2. Parameters showing statistical significance are highlighted in bold.